Propanc Biopharma Sets February 2027 for First Human Trial of PRP Cancer Therapy — Propanc Biopharma, Inc.

Event summary

Propanc Biopharma plans to start a Phase 1b first-in-human study of PRP in February 2027, targeting advanced solid tumors including pancreatic, ovarian, and refractory prostate cancers.
The multicenter, open-label study will enroll up to 50 patients across Australia, with a two-part design focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity.
Manufacturing, bio-analytics, and regulatory preparations are underway, including GMP manufacture of the drug product and submission of supporting documentation to HREC in November 2026.
PRP will be administered as a weekly intravenous infusion in 28-day cycles, with treatment continuing until withdrawal criteria are met.

The big picture

Propanc Biopharma's upcoming Phase 1b trial represents a significant milestone in the development of PRP, a novel therapy aimed at targeting cancer stem cells. The study's focus on advanced solid tumors highlights the unmet medical needs in these areas, particularly for patients with limited treatment options. The biopharmaceutical industry continues to prioritize innovative approaches to cancer treatment, and Propanc's progress could position it as a key player in this evolving landscape.

What we're watching

Clinical Progress: The success of the Phase 1b trial in identifying safe and effective doses of PRP will determine the path forward for Propanc's cancer therapy.
Regulatory Approval: The timely submission and approval of the HREC documentation will be critical for the trial's initiation as planned.
Market Positioning: Propanc's ability to differentiate PRP from existing cancer treatments will influence its competitive standing in the biopharmaceutical market.